TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: delta CP(2h)/delta BS(2h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dosage of insulin used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IL-4 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFN-gamma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability of tramadol
Endpoint domain: Adverse events/effects
Primary endpoint: plasma levels of interleukin-6, norepinephrine, cortisol, and adrenocorticotropic hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: plasma level of interleukin-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: total DRSP Δ‐scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma appearance of C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of GDUs
Endpoint domain: Adverse events/effects
Primary endpoint: lung perfusion assessed by HRCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in ETDRS best-corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in central subfield thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor necrosis factor‐alpha concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histopathological intestinal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sevoflurane utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: prevention of post-treatment transmission of P. falciparum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mortality rate at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Coronary artery calcium score above 400 units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of thoracic aortic aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Referral for additional cardiovascular prevention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pathological fracture rate
Endpoint domain: Adverse events/effects
Primary endpoint: VAS pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Median IELT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEDT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's SLS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: total amount of morphine reduced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cases of nausea, vomiting, pruritus, orthostatic hypotension decreased
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative first anal exhaust time interval shortened
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ratings given by students to the course
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: peak grade 3 mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional outcome at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of IL‐1β in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of IL‐8 in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean adjusted total Unified Parkinson's Disease Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Peripheral Resistance Decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Restriction in physical mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall life situation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-year HUI-2 utility score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 5-year HOQ overall score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Upper arm circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control improvement (GPI decrease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of study time in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of severe hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean ALT activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: H2O2‐E levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of small bowel complications (Grade 3 or 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and duration of OPV shedding and transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: urinary excretion of dopamine, homovanillic acid, free normetadrenaline and free metadrenaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death due to hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Major outcome event
Endpoint domain: Adverse events/effects
Primary endpoint: Increased condom carrying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal-to-noise ratio (SNR) for small vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal-to-noise ratio (SNR) for large vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reaching maintenance dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived quality of life in physical domain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived quality of life in psychologic domain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Net clinical outcome (death, myocardial infarction, refractory ischemia, or major bleeding)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of granulation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Months stayed in institutions for psychiatric patients
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of shoulder ROM reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability of shoulder function assessed by QuickDASH‐TH scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of interstitial fibrosis/tubular atrophy (IF/TA) at month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of subclinical inflammation lesions at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inferior renal function at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in management of common illnesses and pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of flare
Endpoint domain: Adverse events/effects
Primary endpoint: Heart failure requiring rehospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma MCP‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PD20 increase after frusemide inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak Inspiratory Flow (PIF) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flexibility improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of MI for smoking cessation induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain severity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensitivity to thermal stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiation dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of CRC screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost effectiveness of support systems
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total health care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean relative reduction in SCORAD index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug survival
Endpoint domain: Mortality/survival
Primary endpoint: mean brain H1RO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: ACR-ped 70 non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR-ped 30 non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHAQ disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma endothelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work and Social Adjustment Scale (WSAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Vertical astigmatic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged 'on-time' duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in gastritis/duodenitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Age at completion of toilet training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stool toileting refusal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequent constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma erythropoietin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma IL-6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate for IPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average thickness of reparative dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiodensity of barrier formed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preventing death and re-infarction
Endpoint domain: Mortality/survival
Primary endpoint: hemoglobin and iron status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of low zinc intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UTI relative risk
Endpoint domain: Adverse events/effects
Primary endpoint: energy intake per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in LCQ total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean difference in L values between lesional and non-lesional skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total allogeneic units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for tranexamic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SNPs distinguishing successful vs unsuccessful abstainers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of typical postdural puncture headache
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of the severity of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: discounted life expectancy
Endpoint domain: Mortality/survival
Primary endpoint: incremental cost-effectiveness (US dollars/year of life gained)
Endpoint domain: Resource use
Primary endpoint: fatal coronary accidents
Endpoint domain: Mortality/survival
Primary endpoint: survival times
Endpoint domain: Mortality/survival
Primary endpoint: Reoperation risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Leg pain and back function improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 6 Minute Walking Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin secretion (HOMA-%β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average defect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of BDP, 17-BMP, and BOH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ratio of 30 min urinary excretions for Qvar compared with Clenil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rates at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rates at day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of symptoms between days 21 and 42
Endpoint domain: Adverse events/effects
Primary endpoint: Impairment of color vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impairment of dark vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Preparedness for hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total progression-free survival (PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean voids per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Nocturia episodes per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum urgency scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: median total procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total procedure cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean renal growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: worsening frequency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: outcome scores measured by the Toronto scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: larger implant base
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient medication errors
Endpoint domain: Adverse events/effects
Primary endpoint: High or extreme risk medication errors
Endpoint domain: Adverse events/effects
Primary endpoint: GSM score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum OPN levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum OPG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation rate at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarettes smoked per day at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first HF event
Endpoint domain: Mortality/survival
Primary endpoint: less than 15% reduction in left ventricular (LV) end-systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU LOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilator-associated pneumonia per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Accumulated restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unsatisfactory kissing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute gain in side branch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean dissection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of gallbladder perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to normalization of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Libido improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tobacco craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CD19+ B cell depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetic profiles (Cmax, AUCT, AUC0-∞, AUC2-week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of antidrug antibody (ADA) response
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of aphthous ulcer dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of pain reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Obtaining medications within 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean area under the plasma drug concentration-time curve (AUC(0-24)) for budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to respond to verbal command
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angioedema Quality of Life (AE-QoL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: World Health Organization Well-being Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average RNFLT difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of retinal blood vessels in the RNFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first-phase insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Augmentation of ST-segment elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular fibrillation occurrence
Endpoint domain: Mortality/survival
Primary endpoint: radiographic disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary outcome occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of endometritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Supraglottic time to ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fever incidence after coadministration
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titers for dengue serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection against MMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Good knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive attitude towards colorectal screening
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Initial hospitalisation costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: distensibility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: deep dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonmenstrual pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day primary endpoint (death, shock, congestive heart failure and re-infarction)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of CD3⁺ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD4⁺ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bleeding indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: plaque indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes